Department of Urology, Unit 1373, The University of Texas M.D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.
Cancer Prev Res (Phila). 2009 Dec;2(12):1001-2. doi: 10.1158/1940-6207.CAPR-09-0235. Epub 2009 Dec 1.
This perspective on Seager et al. (beginning on p. 1008) considers an important advance in the effort to control bladder cancer. Frontline therapy for superficial transitional cell carcinoma of the bladder involves instillation of the crude immunomodulatory bacterial extract Bacillus Calmette-Guérin directly into the organ. Seager et al. now show that local administration of a chemical inhibitor of mammalian target of rapamycin strongly suppressed growth in a novel preclinical mouse model that develops carcinoma in situ, a particularly problematic form of transitional cell carcinoma of the bladder. The results not only support the clinical evaluation of mammalian target of rapamycin inhibitors in this setting, they open the door for the evaluation of additional molecular local therapies as well.
这篇观点文章是对 Seager 等人的回应（见第 1008 页），探讨了膀胱癌控制领域的一项重要进展。膀胱癌浅表性移行细胞癌的一线治疗包括将粗制免疫调节细菌提取物卡介苗直接注入器官。Seager 等人现在表明，局部应用雷帕霉素的哺乳动物靶标化学抑制剂强烈抑制了一种新的临床前小鼠模型中原位癌的生长，原位癌是膀胱癌中一种特别成问题的形式。这些结果不仅支持在这种情况下对雷帕霉素哺乳动物靶标抑制剂进行临床评估，而且为进一步评估其他分子局部治疗方法开辟了道路。
